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two years ago, I presented my first report as president of The
Rockefeller University. There, I portrayed the distinctive chal
lenges to the University as seen by an enthusiastic new recruit.
With undiminished enthusiasm, I can now bring to my second report a better-informed appreciation of the practical tasks of leader
ship. This periodic stock-taking of our progress is also a re
affirmation of our mission: to seek new knowledge as the most fruit
ful way of achieving public benefit, as well as to sustain the traditions
of a major scientific institution.
The prospects for basic advances and practical "payoffs" from the
life sciences have never been brighter. At the same time, many
forces in the social, economic, and political environment are press
ing on the world of research. Tremors in the global and national
economy erode the institution's reserves and the indispensable
nourishment of basic science from federal funds. The very advances
of biological research in recent decades have evoked both peril and
UST
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promise in the public mind. Clear understanding of the linkage
between basic discovery and applied benefits demands much more
analysis and less passion.
I had the privilege and joy of working at ,the research bench for
more than 30 years before assuming the administrative tasks of
leading a great institution and explaining it to those from whom we
seek support. On the basis of that experience, I honor these chal-·
lenges as a personal and institutional opportunity to respond with
confidence and credit. This report will stress the issues raised by the
. very complex external environment in which science today must
play its part. In that environment, our own institution has a special
role. In order to succeed in it, we must respond to society's expecta
tions of science and technology and must articulate our mission in
the system of scientific discovery, technological design, and public
dissemination of their fruits.

Rockefeller University: Then and Now
This University was founded, as The Rockefeller Institute for Medi
cal Research, some 80 years ago. It was designed to launch the
scientific investigation of medical problems in this country and to
match the heroic accomplishments of European medical science,
symbolized by such "Microbe Hunters" as Louis Pasteur and Robert
Koch. Here, too, infectious diseases took the center stage� but the
Institute's p.rst director, Simon Flexner, also emphasized the most
fundamental research in biological and chemical science. From its
beginnings, The Rockefeller has always encouraged a balanced con
vergence of clinical investigation and basic scientific activity. Many
scientific advances had their roots in the wards and laboratories of
The Rockefeller University Hospital. In turn, many clinical insights
have been inspired by basic findings in biology and chemistry.
Nevertheless, many medical institutions are experiencing the grow
ing divergence-even alienation-of these two streams of investiga
tion, a trend we work to forfend.
During the early years, The Rockefeller, thanks entirely to the
generosity of a single private donor, enjoyed a remarkable share
initially almost half-of the total investment in medical research in
the United States. The Institute soon achieved preeminence in the
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scientific life of the country and furnished a model for the creation of
similar research centers. That tradition of leadership is today a
unique asset and responsibility, but the national investment in
biomedical Fesearch and its allocation have, of course, changed
dramatically. In 80 years, as measured by annual budgets in "con
stant dollars," the University has grown by a factor of about 15, but
medical research nationally has grown by a factor of 1,000 (Chart 1,
page 4). Most of the national increase and three-fourths of our
University's were made possible by the commitment of federal
funds, through the National Institutes of Health. Having been thus
emulated on a very large scale, we now account for barely one per
cent of the national expenditure in biomedical research. Our special
impact is now expressed by the quality of our people and our distinc
tive organization and traditions, rather than by gross level of effort.
It in no way diminishes the Rockefeller family's role, in the
founding and early growth of the University, that their personal gen
erosity cannot alone shoulder the vastly expanded costs of a mature
institution. The scope and expenses (some $55 million in 1980-81)
of this university of science would have been unimaginable when
the first few laboratories were opened in the early 1900s. The largest
part of this growth is represented by numbers of laboratories, the
wealth of scientific specialties that give the University a formidable
profile in almost every pertinent area-from molecular and cell biol
ogy to behavior and clinical investigation. A related investment that
has borne valuable fruit was the introduction in 1954 of the graduate
fellows program, the formal scientific training leading to the Ph.D.
degree that was associated with the change of name from Institute to
University.
For much of the '70s, the University, like many other institutions,
was seriously buffeted by escalating energy costs, general price
inflation, and the slowdown of federal support. Substantial deficits
enforced a tighter rein on expenditures, a realistic adjustment of
self-image, and a reexamination of its central purposes. The conclu
sion was to focus on our institution's traditional success in a bal
anced program centered on biomedical research, like that inspired
by Flexner. This would necessarily be extended to include studies of
the behavior of the entire organism and to draw on special insights

4

The Rockefeller University

Chart 1. Expenditures for Biomedical Research
(Constant Dollars)
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In 80 years, Rockefeller University expenditures on biomedical research have grown fif
teenfold, total national expenditure a thousandfold. The University now accounts for one
percent of national investment in biomedical research.
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fro"m the mathematical and physicai sciences. Unlike many larger in
stitutions, however, we are not hostage to large-scale fixed obliga
tions for undergraduate education or general medical services.
Hence, we can continue to work within a simple administrative
structure-with individual laboratories reporting directly to the
president-that avoids the politics and overhead of potentially
divisive departments and separate specialty schools.
The University's successful discipline in a time of economic in
security has helped us to inspire the support of many private donors,
reached by a general fund-raising effort organized barely ten years
ago. With their help, the University has been able to balance its fiscal
accounts and to make a realistic projection of future needs and
resources. The model envisions that the University will continue to
maintain its present scope and mix of programs, with 55 or 60 la
boratory groups. A dynamic equilibrium will be achieved by balanc
ing retirements of laboratory heads with new tenured appointments
and promotions. Each such opportunity will be the occasion for a
fresh examination of the University's needs and priorities. It will
also be a time to allow for the continuing professional advancement
of our most talented younger faculty. Within the limits of a balanced
size, our system thus provides for evolutionary changes to meet new
scientific opportunities, unencumbered by squatters' rights of exist
ing specialties and departments.
This might appear to be an unglamorous model for the future,
building as it does on our past traditions. To the contrary, we should
be reassured that The Rockefeller has exhibited extraordinary
breadth and strength in its established disciplines. With a few excep
tions, these evolutionary accommodations provide ample openings
for fresh insights and new technical approaches. Our present size en
courages a quality of collegial communication that would be diluted
by rapid growth, even if this were permitted by available fiscal
resources.

Biomedical Research Today
In many ways, The Rockefeller University is a microcosm of the na
tional effort in medical research. Economic strictures in federal
funding for basic science have been less a general cutback than an
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end to growth in available resources. This has already collided with a
hard-won fruition of maturing and capable scientists who have enor
mous potential for making contributions to scientific and medical
knowledge.
This disparity between shrinking funds and burgeoning talent and
scientific opportunity has intensified the competition for established
resources and positions. It has eroded the stability of support for
research programs. It aggravates the anxieties of investigators about
their opportunity to continue research. It tends to immobilize them
in location and in scientific interests. It impels them to spend enor
mous amounts of time and emotional and intellectual energy in en
trepreneurial ("grantsmanship") activities at the expense of their
central passion and responsibility. By maintaining a stable setting for
a faculty of excellence, The Rockefeller University makes an ex
traordinary contribution in substance and by example. The ebb and
flow of government support and the rigidities it imposes (in the
name of accountability) are a major source of the pressures. Hence,
it is the University's autonomy as a privately supported institution,
that bridges the financial gaps and crevices left by spasmodic public
funding. Not for many years has it been possible for any institution
to match from other sources the federal support it received for the
major portion of its research expenses. However, even modest gen
eral funding for this bridging of contingencies greatly amplifies the
efficacy of government funding.
The University has a �ost successful tradition of supporting and
developing creative leaders in research. Hence, programmatic orien
tation tuned to trends in research support takes second place to sus
taining an effective style of research career. We aim to furnish first
class investigators the freedom to set their own directions and deter
mine their own research objectives. For the University to continue
to do so will require extraordinary effort in the face of global
economic difficulties and their impact on government, corporate,
and individual philanthropic investment in science. The commit
ments made by the University to its faculty and major programs span
decades. The funds to meet them must be anticipated and provided
for over a much longer period than their sources can be accurately
foreseen. The most reliable long-term source of funds- the real in-
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come from endowment-covers scarcely a fourth of our operating
budget. However, this is the margin that enables us to underwrite
our plans against the uncertainties of year-to-year support.
No single measure of inflation assures an authentic picture of the
institution's financial standing in a single year. For example, the re
cent high interest rates resulted in a temporary rise in our revenues.
On the other hand, many of our future expenses will, no doubt, in
crease in the same measure, but will not all be reflected in a single
annual statement. In addition, the Uni':1ersity is just now catching up
with many long-delayed maintenance tasks and laboratory renova
tions. However, our ten :.. year projections-premised on sustained
effort in our development program-show a continued equilibrium
of income and expenditures. These forecasts are the most realistic
tools for long-range planning. Table I on page 8, prepared by David
J. Lyons, the University's vice president and controller, is another
effort to review the stability of our endowment reserve through the
turbulence of the last decade. The outcome is, of course, highly sen
sitive to conflicting measures of real costs of research, but it does
provide reassurance that the University can manage its affairs suc
cessfully even through such storms.

Sustaining Public Confidence
Despite the leveling off in federal funding, biomedical research still
enjoys a privileged place in the expectations of the public. The NIH
and similar programs were almost the only ones, besides national
defense, to escape crippling wounds in the 1982 federal budget.
Continual strictures in federal expenditures have, however, made
deep inroads in the integrity of many programs in research and gra
duate training.
We have a special opportunity and obligation to sustain public
confidence, and the University's concern for critical scrutiny of our
research converges with that of the larger society. This is directly re
lated to the ongoing renewal of our faculty. The premise of our sys
tem of career appointments is the most stringent selection of those
who receive them. In exchange for that stringency, the University
gives those appointed the widest encouragement and the support
they deserve as leaders in the difficult paths of scientific discovery.
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That so much responsibility is delegated to the laboratory heads is
precisely why these choices must be so closely scrutinized. The first
criterion is, of co�rse, the investigative excellence of the candidate.
Then we may optimize our choices with respect to the fit of a candi
date to the institution's primary mission as a biomedical research
center and a community of scholars, and to other dimensions of
campus life.
No one can accuse- this institution of making its choices on the
basis of parochial relevance. Historically, the University's most dis
tinctive characteristic has been the conviction that our explorations
need but go deep enough for discovery to relate to profound human
benefit. Nonetheless, we must recognize that outside forces often
demand short-term yields that are simply unachievable: least of all
by insistence on "targeted" research. The NIH budget is, in fact, the
largest federal commitment to basic science: a preponderance that is
socially justified by benefits to public health that derive from the
most fundamental knowledge of living systems. This is not a univer
sally recognized linkage. For one thing, the partial successes of semi
empirical medicine with vaccines, antibiotics, and psychotropic
medications have obscured how incredibly crude our insight is about
how and why these interventions work-how far medical scientists
are from the kind of understanding that unites the physicist and the
integrated-circuit design engineer. It is not lack of ingenuity or dili
gence; it is the inherent complexity of living organisms-above all
the human-that frustrates our moving medical care and preventive
health into the realm of design enginering. To meet such an ambi
tious goal entails still more basic research, on a scale that would
remain a small percentage of expenditures on health care. Despite
many isolated improvements, the overall limits to our success in
dealing with cancer, even during the last decade, illustrate the short
fall in our needs for basic biomedical knowledge.
In any event, there remains a needless and damaging alienation
between the adherents of this view and those who seek to accelerate
application of the advances we have made. The alienation arises, in
part, from the understandable anxiety of basic scientists about the
seeming social ambivalence regarding the support of their efforts.
Further confusion stems from the fact that the practical dissemina-
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tion of health technology is not in the hands of scientists; but is the
preserve of two other communities-the medical practitioners and
the pharmaceutical industry. These two groups are closely coupled
to a health economy with very large revenu.es. Basic research is not.
Considering the attendant pressures so evident on the public scene
today, it would be a mixed blessing if basic research were so coupled.
The research laboratory is not well organized to get "results" in a
sphere that depends more on market analysis than it does on
scientific understanding.
Equally unfortunate is the quarrel between some advocates of
public policies for preventive health and of rational medicine. There
is no controversy that disease-prevention is vastly preferable to the
most sophisticated of cures. It is also true that important improve
ment to personal health is achievable by commonsense attention to
lifestyle (e.g., diet, smoking, use of alcohol and other drugs, exer
cise, and sleep). While we have long since set aside prohibition as an
answer to alcohol abuse, there remains a widely held attitude that
disease is the penalty of sinful life. The fact remains that many
heart-disease victims are not obviously stigmatized by their lifestyle,
and that the health penalties of aging will be with us regardless of
personal hygiene. The delineation of the most important and useful
elem_ents of personal behavior and of environmental protection is a
cogent challenge to the most sophisticated biomedical research. So
also are the factors that entrain people into behaviors they well know
to be self-destructive.
We may recall that, in the last century, cholera was believed to be a
visitation for sin� many still place sexually transmitted diseases in
that category today. Whatever the merits of these views as moral
philosophy, they have been far less productive of material health ad
vances than an understanding of the biology of the causative organ
isms and development of specific measures against them (Chart 2).

A Question ofBalance
Yet it is uncertain whether scientists have been able to articulate a
sufficiently persuasive response to the taxpayers' expectations. Both
in rhetoric and in policy, we face a delicate task of balance for our
own institution, to maintain its distinctive genius, and to fulfill the
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Chart 2. Major Causes of Death in the United States 1900-1975
1900
Crude Death Rate
16.2 per 1,000

1940
Crude Death Rate
10.6 per 1,000

1975
Crude Death Rate
9.0 per 1,000

Causes of death: In these crude death rates, the largest factor in the shift is the "conquest"
of infectious disease and the resultant rising age level, as shown by the increase in cancer
and heart disease.
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mandate of our motto: pro bono humani generis. Of course we should
eschew applied research tasks to which we are ill-suited. However,
there is no contradiction between hewing to our pursuit of basic
knowledge and educating ourselves about t�e realities of disease as a
rich source of puzzles of biological behavior that stimulate our
theoretical imagination. Nor should this mandate for a well-knit in
stitution be confused with intrusive and unrealistic demands on in
dividual investigators. We may again look to Simon Flexner's initial
conception of a balanced institution encompassing an unbroken
spectrum of basic to clinical investigation, from the laboratory to the
research-hospital ward. Many universities and medical schools have
jeopardized that balance, and weakened support for and useful in
tercommunication with the basic sciences, by assuming the obliga
tions of large teaching hospitals and the related heavy and self
aggravating burdens of service and practice. This development
deepens the imperative that we sustain The Rockefeller University
as a place where clinical investigation can be significantly represent
ed without swallowing up the entire research effort. That clinical
component, embracing research on distinctive problems of human
biology and pathology, makes it impossible to put out of mind the
grievous ills which we have an obligation to alleviate. It also alerts
our scientific community to pathobiological processes, information
that time and again has opened our eyes to previously ignored
phenomena of the most fundamental biological importance.
Under the leadership of Attallah Kappas, The Rockefeller Uni
versity Hospital is engaging in a significant renascence of its pro
grams. Notable are major new efforts in endocrinology and derma
tology. The focus of interest in endocrinology in the laboratory
headed by Jack Fishman is on the biology of steroid hormones with
particular emphasis on their role in human phy�iology and patho
physiology. The laboratory of cutaneous biology and investigative
dermatology, under D. Martin Carter, will explore fundamental
mechanisms that are operative in the disabling skin diseases.

Complementary Institutions
In the University's continuing effort to maintain an optimum bal
ance in its research efforts, we have a considerable advantage in the
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close proximity of two major patient-intensive hospitals-Memorial
Sloan-Kettering Cancer Center and The New York Hospital-Cornell
Medical Center. The development of a dermatology program at our
hospital was made possible by opportunities for research collabora
tion with New York Hospital-Cornell. Similar collaborations are
under discussion with the Population Council's Biomedical Re
search Division, whose laboratories are situated on our campus, and
with Memorial Sloan-Kettering.
It is in clinical research that our strengths and interests most evi
dently complement those of our neighbors. We are also seeking
every other means to further the maximum good from our collec
tive human and physical resources. The three institutions at the in
tersection of York Avenue and East 68th Street are-by world
standards-a formidable concentration of medical interests, ser
vices, and science. Increased communication and collaboration
within this complex will go far to ensure that our scientific efforts are
informed by human health needs. In turn, no opportunities will be
overlooked to go from research advances to practical application at
the earliest occasion. In addition, choices of programs to be further
emphasized can be made in the light of existing strengths within the
complex.
The metropolis has a rich academic culture at many other places ,
as well, and as a specialized center we are particularly grateful for that
environment.

Public Health Problems
If there is a significant weakness or imbalance in the complementary
efforts of the three institutions to address human concerns, it is re
lated to certain widespread problems of public health and preventive
medicine. This imbalance is national, even global,- and stems from
the relative poverty orfunding available for research programs not
related directly to an existing and potentially remediable disease.
Especially impoverished is work on the parasitic scourges, which pri
marily attack the populations of developing countries, locked in a vi
cious cycle of ill health and low economic productivity.
In the latter category, we are continuing our traditional support of
work in parasitology with a particular view to unifying it with modern
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developments in molecular and cell biology. These will have most
exciting, as well as useful, applications for such tropical diseases
as malaria, trypanosomiasis, schistosomiasis, leishmaniasis, and
filariasis-scourges happily almost unknown in this and other of the
more developed countries, and for that reason grossly neglected. It
is with particular gratification that we can announce the recent ap
pointment of George Cross, a molecular parasitologist, who will
come here from England. We will also be working closely with The
Rockefeller Foundation's global network on the "Great Neglected
Diseases," for example in the organization of summer laboratory
courses at the Woods Hole Marine Biological Laboratory.
In the category of protective health problems not directly related
to disease, a vitally important research need is an effort to put en
vironmental toxicology on a scientific base. The last decade has seen
a dramatic awakening of public concern over the injurious effects of
certain substances. This is a long-overdue reaction to neglect and ig
norance of the power of an industrial society to pollute even the glo
bal environment. It has been accompanied, however, by stringent
regulatory controls that threaten to hinder industrial development at
a time when our economy is already under heavy pressure. These
costs may be unavoidable in the light of potential hazards to public
health, but in the present state of our knowledge they are too often
inflicted on the basis of alarm rather than proven assessment of ha
zard. This unproductive impasse cannot be a stable basis for national
policy, and any improvement must be based on sharper tools for
predicting the actual hazards to human health from exposures to
substances for which some alarm has been elicited from limited la
boratory findings. That the Congress has singled out saccharine for
exemption from the prevalent standards of food-additive regulation
illustrates the arbitrariness of judgment that now prevails.
Toxicology, as an academic discipline, has suffered sharply from
being too tightly coupled with routine regulatory test demands. In
fact, as a scientific challenge, toxicology is intimately connected with
the most intricate issues in molecular and cell biology. Many of the
most basic discoveries in metabolism and in neurobiology stem
from the investigation of toxic effects of particular substances. With
the gratifying endowment of The R. Gwin-Follis-Chevron Chair by
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the Standard Oil Company of California, we are in the position to
seek the leadership for a major program in comparative toxicology.

The Basic Sciences
(

The areas of clinical and public-health science just surveyed have, of
course, the most immediate relationships to the practical problems
that are the justification for public investment in The Rockefeller
University. In danger of being overlooked is the intricate connection
between these public fruits and the basic scientific work that fully
defines our mission. Historically, the University has made innumer
able and invaluable contributions to public health. These include the
development of vaccines, the transfusion and preservation of blood,
the monitoring of body metabolism in pathological states, research
underlying organ transplantation, and a host of other therapeutic
techniques. Such advances are indispensable to the really important
triumphs of medicine, but only the most sophisticated of observers
could know the distant origins of such triumphs in the laboratories
of the biochemist, molecular biologist, or biophysicist. The basic
contributions are overshadowed by the communities of other tech
nologists and practitioners, who interface much more directly with
the public.
A notable example is the discovery of the biological significance of
DNA, brought to light in 1944 by Oswald Avery, Colin MacLeod,
and Maclyn McCarty (page 16). The historical links between that
momentous discovery and the current technological breakthroughs
in recombinant DNA methods and genetic engineering are unambi
guous and well known within the scientific field. However, it would
be hard to find a mention of them in the prospectuses for new indus
tries spawned by DNA science� nor is there any direct way that the
University can be rewarded, precisely because this was such a funda
mental discovery. Could the interval of more than 35 years between
discovery and invention have been shorter? Probably not, in view of
the extensive superstructure that had to be built on the initial
finding.
When it comes to medical applications, I have sometimes asked,
during the past decade, whether DNA science has yet made a contri
bution to medical practice to match the revolution it had brought

Oswald T. A very

Colin M. Macleod

Maclyn McCarty

STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE
INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES
INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC

Acrn

FRACTION

ISOLATED FROM PNEUMOCOCCUS TYPE III

BY OSWALD T. AVERY, M.D., COLIN M. MACLEOD, M.D., AND
MACLYN McCARTY,* M.D.
(From the Hospital of The Rockefeller Institute for Medical Research)
PLATE

1

(Received for publication, November 1, 1943)
Biologists have long attempted by chemical means to induce in higher
organisms predictable and specific changes which thereafter could be trans
mitted in series as hereditary characters. Among microorganisms the most
striking example of inheritable and specific alterations in cell structure and
function that can be experimentally induced and are reproducible under well
defined and adequately controlled conditions is the transformation of specific
types of Pneumococcus. This phenomenon was first described by Griffith (1)
who succeeded in transforming an attenuated and non-encapsulated (R)
variant derived from one specific type into fully encapsulated and virulent (S)
cells of a heterologous specific type. A typical instance will suffice to illustrate
the techniques originally used and serve to indicate the wide variety of trans
formations that are possible within the limits of this bacterial species.
Griffith found that mice injected subcutaneously with a small amount of a living
R culture derived from Pneumococcus Type II together with a large inoculum of
heat-killed Type III (S) cells frequently succumbed to infection, and that the heart's
blood of these animals yielded Type III pneumococci in pure culture. The fact that
the R strain was avirulent and incapable by itself of causing fatal bacteremia and the
additional fact that the heated suspension of Type III cells coutained no viable or
ganisms brought convincing evidence that the R forms growing under these condi
tions had newly acquired the capsular structure and biological specificity of Type III
pneumococci.
The original observations of Griffith were later confirmed by Neufeld and Levin
thal (2), and by Baurhenn (3) abroad, and by Dawson (4) in this laboratory. Subse
quently Dawson and Sia (S) succeeded in inducing transformation in vitro. This
they accomplished by growing R cells in a fluid medium containing anti-R serum and
heat-killed encapsulated S cells. They showed that in the test tube as in the animal
body transformation can be selectively induced, depending on the type specificity
of the S cells used in the reaction system. Later, Alloway ((,) was able to cause
* Work done in part as Fellow in the Medical Sciences of the National Research
Council.

Opening page of the DNA paper, published in 1944 in TheJournalofExperimemalMedicine
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about in biological research. To pursue this question, we should re
view the development of biomedical research of the past century.
About a hundred years ago, the germ theory of disease was the
principal foundation of modern scientific medicine. Antisepsis
saved innumerable lives in childbirth and in surgery. Elementary
hygiene and protection of food and water supplies from contamina
tion saved even more. As bacteria were grown in pure culture and
identified as specific agents of disease, vaccines could be developed.
The aspects of applied medical microbiology concerned with bacteria
reached their zenith in the 1950s with the wonder-drug antibiotics,
which have totally reversed the odds in the battle between afflicted
patients and many infectious invaders. The development of polio
vaccines soon after was a similar culmination, in the public's aware
ness, of the application of basic findings in virology to the conquest
of infectious diseases.
The human benefits from scientifically informed attack on the
problems of infectious disease are incalculable. Lamentably, we
have not seen the last of threats to health from microbes and
viruses. Antibiotic-resistant pathogens evolve in the most trouble
some way, and may yet provoke major epidemics difficult to control.
Vaccines for pneumonia, having been preempted almost 40 years
ago by sulfa drugs and antibiotics, have been dusted off the shelves
and are reemerging as a delayed fruit of the Rockefeller Institute 's
research. Most virus infections still defy systematic treatment: only
with a clear understanding of the genetic structure and evolutionary
potential of the influenza virus, and of its protein structure, can we
develop fully effective prevention for this debilitating disease, which
may affect tens of millions of people in an epidemic year.
This extraordinary success of medical science between 1880 and
1950 was the main inspiration for vigorous national support of
research modeled largely on The Rockefeller Institute: the federally
funded programs of the National Institutes of Health. However,
with these same dramatic successes against infections, our priority
health problems have shifted to heart disease, cancer, and psychia
tric illness. The inherent intricacy of these problems, which are root
ed deeply in the molecular and cellular structure of the human or
ganism, outreaches the existing base of applicable scientific
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knowledge. This ignorance has frustrated the building of a theoreti
cal program for the control of these killers comparable with the ad
vances in the golden age of bacteriology to which Rockefeller scien
tists made such historic contributions.
This frustration is partly obscured by a number of valuable piece
meal advances in all of these fields, by the proliferation of high
technology diagnostic machines, and by the development of
scientifically trained, sophisticated specialties to make these accessi
ble to patients. This technological revolution has also carried a heavy
price tag, and some political pressure for cost-reduction that would
better be directed to benefit-improvement. The training of these
specialists has been the main contribution of academic medical insti
tutions to today's "half-way technology" in medical care. Most of the
important new drugs of the past 30 years have been discovered
through empirical, not rational, procedures and in industrial, not
academic, laboratories. Empirical as they are, these discoveries also
depended on an infrastructure of scientific knowledge to calibrate
how drugs like aspirin, chlorpromazine, or thiazides can best be em
ployed. Equally important, a host of spurious remedies would be
firmly planted in our medicine cabinets without the certification of
efficacy and safety that must be informed by the most rigorous
scientific judgment.
This perspective on recent medical science is a controversial one.
It deviates from the optimistic forecasts of the 1950s and from the
"crusade against cancer" of the '70s that seemed to promise an early
solution to these pervasive health problems. Many believe in a more
rational reductionist approach to medicine that would be firmly
based on rigorous scientific knowledge, and would give academic la
boratories greater credit for practical health advances. In fact, I
firmly espouse that view; my critical reflections have to do with the
time-scale of these expectations, and with an authentic reading of
the actual history of the last 30 years. My greatest fear is that
scientific insight is dissynchronized with public understanding. In
stead of sensing the remarkable opportunities through which sci
ence can contribute to society-opportunities that, historically, oc
cur in cycles-the public may become disillusioned; the result could
be retrenchment of research support.
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The current cycle is impelled by the most fundamental of biologi
cal sciences, the study of DNA and proteins. It can now be estimated
that the human body contains some 100,000 different and distinct
categories of proteins. As organisms, we are a hundred-or a
thousandfold more complex than the microbes we target in warding
off infectious disease. Today, we have some skimpy knowledge of
perhaps 1,000 of those human proteins: we have scratched the sur
face to a depth of one percent! Almost everything we attempt in ra
tional medicine is connected with the structure and behavior of pro
teins. We stumble in a dark cave, guided more by intuition and trial
and-error than by a readable topographic map. Our hopes for radical
interventions to prevent or reverse such complex processes as canc
er or aging can scarcely outpace that knowledge.
Until about ten years ago, our methods enabled only crude
guesses at these orders of complexity. Today, news of DNA per
vades the stock mark.et. It may be woefully ill-informed in detail, but
it has accurately mirrored the confidence and energy of investigators
who are rapidly developing these new biological tools at an escalating
pace. No prophecy can be safe: but all of the.crucial disease threats to
human life now fall within the reach of fundamental molecular and
cellular investigation. Just this scientific base remains the main core
of The Rockefeller University's programs. If we can sustain our
courage, critical candor about the historic stages of development of
medical science, and public confidence, we can indeed complete a
new cycle of health benefit to match that of the heroic conquest of
bacterial infection. To underestimate either the hurdles or the fruits
will vitiate our effort.

The Spectrum ofScience
The breadth of the University's commitment to fundamental biolo
gy defies compact summary. It can be found in the reports of the ma
jority of our laboratory groups. Their work ranges from the ultra
structure and biophysics of cell membranes to the neuronal basis of
bird song. This institution has been designed to be of such a size and
scope that it can just encompass almost every important field of bio
logical investigation, and is s�ructured so as to facilitate communica
tion among its specialists.
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A few words, then, about several movements for change within
this well-established setting. The neurosciences have been an im
portant tradition at Rockefeller University. For example, its second
director, Herbert Gasser, was a pioneering,neurophysiologist who
introduced the oscilloscope into that line of research. For the last 20
years, a fertile intersection of neurophysiological research with the
integrative outlook of the behavioral scientist has been the contribu
tion of Carl Pfaffmann and the group he helped to develop at the
University. Recent and imminent retirements now impel a special
emphasis on renewal in this general field, and we have been mar
velously assisted by the benefactions of the Astor Foundation. In
my next report, I hope to announce several recruitments.
We can already take pleasure in the move now underway to our
campus of the Neurosciences Research Program (NRP), formerly at
Boston, Massachusetts, and presently directed by Vernon B.
Mountcastle of The Johns Hopkins University. The NRP is spon
sored by the Neurosciences Research Foundation under the chair
manship of William T. Golden, a member of The Rockefeller
University Council. One of the major activities of NRP at The
Rockefeller University is a new Neurosciences Institute� Gerald M.
Edelman of our faculty, who serves as scientific chairman of NRP,
will be its director. Working with Dr. Edelman, a scientific advisory
committee directed by W. Maxwell Cowan of the Salk Institute will
extend invitations to brain scientists the world over who wish to use
the facilities of the Institute. Visits by these scientists will enrich
communications here and elsewhere and help us to understand the
challenging problem of the basis of higher brain function.
Similarly, the University recently reaffirmed its longstanding in
terest in the lessons to be learned from the botanical world. In the
new laboratory of Nam-Hai Chua, DNA methodology has been ap
plied to study fundamental aspects of protein synthesis that are im
portant to the efficiency of plant photosynthesis. This research could
have an important bearing on the improvement of the productivity
of major crop plants and testifies to the continued vigor of a universi
ty tradition pioneered by Louis 0. Kunkel, Wendell Stanley, and Ar
min Braun.
Advances in molecular biology have gone so far that one possibly
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overenthusiastic commentator has bewailed the looming lack of un
solved scientific problems. That may be for the next millenium;
meanwhile the translation of genetic blueprints into the fabric of the
organism, i.e., the problem of development, is one of our most ur
gent and exciting challenges. We are gratified at the further rejuve
nation of our research programs in this field through the recruit
ment of Robert Roeder, a world-esteemed colleague who may well
be said to substantiate the traditions established at our founding by
Jacques Loeb.
Some of the proudest accomplishments in the University's histo
ry have concerned the structure of enzymes-their chemistry as
protein chains of amino acids, and how their shape endows their
near-miraculous role in metabolism. These structures are the work
ing machinery of the cell, the material product of the DNA genetic
blueprints. To sustain our leadership in this field, we are gratified
that another world-eminent figure, Emil Thomas Kaiser, will short
ly be joining us. His research to date has been notable in its applica
tion of rigorous physico-chemical measurement and construction to
fundamental and to practically important biological problems.

Physical, Mathematical, and Computer Sciences
Mathematical reasoning is the ultimate tool of rational human
discourse. We cannot truly claim theoretical understanding of a na
tural phenomenon until we apprise it well enough to express our
models in mathematical notation. Then, and not before, they are
amenable to formal verification and search for inconsistencies and
further implications. To a large degree, physics and chemistry have
been unified through this process. By allqwing us to approach
rigorous calculations of the shapes and attractive forces of organic
molecules, these studie� have already helped to- place molecular
biology and pharmacology on a more sturdy theoretical basis.
Mathematical calculations are also beginning to help us manage the
complexity of the nervous system: How else could the human brain
hope to understand its own complexity? Finally mathematical statis
tics is an indispensable underpinning for testing hypotheses in ex
perimental biology and medicine, and especially for studies in popu-.
lation biology and epidemiology.
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Nevertheless, much of contemporary biological research is
beyond the reach of mathematical theory: the rules do not lend
themselves to precise expression with existing algebras and in the
present state of our knowledge. Rapid advances in molecular biology
are beginning to allow us to treat living phenomena with greater
rigor, and there is then some hope of the feasibility of a more
mathematical theory for biology that should help knit together the
various branches of study, both within biology and in its relation
ships to physics and chemistry.
It is not easy to prescribe how to reach such a goal, but The
Rockefeller University with its capability for interdisciplinary study
has a speci�l responsibility. We are in the course of an analytical
study of the place of mathematics here, whose outcome cannot be
anticipated, especially as limited resources will oblige us to select
only the most persuasive of a group of desirable options. The issues
to be considered must include: a) What is the current status of
mathematical biology, and who are its most effective exponents? b)
How can we best expand our efforts in the physical sciences, most
effectively to bridge the gap between the small, superb group in
high-energy physics and the main body of research that deals with
molecular rather than subatomic phenomena? c) How to take ad
vantage of the explosive developments in computer science and
technology? And all of these in a fashion that engenders an organi
cally effective, overall program here.
The Rockefeller University has been among the pioneers in
biomedical electronic instrumentation� it is then ironic that it should
have been relatively tardy in the applications of general-purpose
computer technology and information science. This can be under
stood in light of the extensive framework of engineering and other
technological capabilities that are centered outside the biomedical
sciences, and can only be found at the largest general university
centers like Stanford and MIT. We cannot indefinitely ignore these
developments, especially as the costs of computing hardware, and
general access to computing centers through digital telecommunica
tions, bring these capabilities within our reach. Besides the well
established role of computers in mathematical calculation, the link
age of computers with communications can greatly advance library
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information services, administrative management, personal sci
entific interactions, and the individual's own extended memory. In a
word, this technology is indispensable for the kind of institution we
describe ourselves to be.
To date, we have taken only the first steps in establishing a sophis
ticated computer network, with the installation of modest-sized
DEC (PDP-11/70 and V AX-11/780) machines and a campus net
work through our telephone lines. This offers document-processing
as well as mathematical-calculating services, and during the next de
cade should become the most robust medium of personal communi
cation, as well as information-storage and -retrieval on the campus.
This document, for example, is one of the first of our university
publications to be fully drafted, edited, and prepared for print on our
system. We are most grateful to Bell Laboratories, Inc., for their as
sistance in mounting the UNIX™ operating system, which has been
designed to meet a similar range of needs.

Relations with Industry
We are entering an era when the industrial sector is bound to be
more important in university policy for many converging reasons.
The leveling of federal support is only the most superficial of these.
Perhaps the most important is the national need for the revitaliza
tion of our economy through technology, and of individual produc
tivity through the enhancement of human skills. Industrial funding
is now indispensable for not-for-profit institutions. In addition, new
forms of tangible cooperation, through the convergence of comple
mentary skills and backgrounds, can offer many other advantages.
Yet, there is an undeniable and intrinsic source of conflict, namely
between the proprietary interest of a single firm and the public
responsibilities of the institution. However, this conflict can be
managed and contained to achieve many countervailing benefits.
The University should not forget or confuse its distinctive role as a
fount of fundamental knowledge. Nevertheless, it can be a clearly
identified partner with sponsors, if mutual interests serve practical
purposes. But it must not become a captive of particular interests,
lest it fail its public responsibilities and antagonize other potential
partners.
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These are not easy issues to resolve, and relations with industry
will continue to demand the most careful deliberation and max
imum understanding among faculty, president, and trustees. For
tunately, the organization of this University into distinct labora
tories enhances our flexibility in dealing with industrial sponsors.
Each laboratory is a unit large enough to be important in its field of
research, yet small enough for agreements to be negotiated respon
sibly� as a result, the funds involved in a given transaction with any
one laboratory will not be thought to distort the institution's overall
priorities. The University's role is to be a responsible agent, to pro
tect the faculty against undue intrusion on academic prerogatives
and freedom, to ensure that external agreements do not abuse other
elements of the University, and to negotiate in ways that do fairly re
ward the institution. Above all, we have the pro bona responsibility
of helping to accelerate useful applications of scientific advances.

Life on Campus
The daily stresses that affect the life of science are ameliorated at
The Rockefeller University by the spirit of the campus community.
The tranquil beauty of the campus, especially in contrast to the stri
dency of the city, is an irreplaceable asset.
These surroundings are the setting for another unmatched
asset-a staff with a truly impressive range of skills and talents and a
rare level of dedication. Probably only those in this research com
munity can ever know how much the University's success rests on
the skills of the entire staff-office workers and instrument-makers,
nurses and gardeners and technicians, engineers and cleaners. Their
competence and pride, and in many cases their ingenuity and even
heroism in the services they provide, have been extraordinary over
the years.
Perhaps the most intangible of our attributes is the quality of com
munication within our group of scholars. The Rockefeller Universi
ty was designed for interdisciplinary efforts, and for the intellectual
revolution that can attend them. This kind of effort does not come
naturally. In various ways it flies in the face of many structural obsta
cles in contemporary institutions. Witness just the fragmentation of
federal support via splintered project grants. When the University
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was much smaller and more tightly directed, it was far easier to sus
tain a coordination of mutual interest. Our laboratory heads, who
number fewer than 60, can more readily sustain an institutional
orientation. Our junior faculty and fellows number some 500, and
their responsibilities to an individual laboratory may add to the
difficulty of relating to the overall community. A number of devices
are in play to help provide a reasonable balance of focus and perspec
tive for the professional activities of this group. For example, a
weekly colloquium is a long-standing, traditional forum for the en
tire University. Nevertheless, so much of our energy during the past
decade has been consumed by fiscal crises that we should now seek
further measures to help us function as an intellectual community,
with the utmost cross-stimulation and criticism. The overall size of
an institution may be an intrinsic obstacle to that easy intimacy of
minds, but this is a task that must engage all of the wisdom of the
campus. As we succeed, our campus community will continue to
stand as a model for collegiality of scholarship.

Financial Trends
Financial operations for the year ended June 30, 1981, showed im
provement from the previous year and, for the second consecutive
year, revenues exceeded expenditures. Table 2 summarizes reve
nues and expenditures, including capital budget operations, for the
last three fiscal years.
The amounts in Table 2 do not include the approximately
$26,550,000 in net additions to endowment and similar funds dur
ing the three-year period. These funds provide additional invest
ment income (see line 3, Table 2) which helps to offset the decline in
purchasing power of the current investment income.
Chart 3, page 27, shows the trend in revenues for the last ten
years. There are three basic sources of revenues: investment in
come, private gifts and grants, and government grants. The "other
revenues" are primarily associated with the self-balancing opera
tions of housing, food service, and The Rockefeller University
Press. Development efforts were first begun in 1972; the subse
quent growth in private gifts and grants and the increased invest
ment income from additions to endowment funds have provided
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the opportunity to manage the large increase in governmental funds
without losing flexibility or control of institutional priorities.
Chart 4 shows the different components of revenues and expendi
tures with the related percentages for the fiscal year ended June 30,
1981.
The market value of endowment investments at June 30, 1981,
was approximately $270 million. Independent analyses of our port
folio by Merrill Lynch over an extended period of time show that our
professional management has produced exceptionally good results
when compared with other funds with similar objectives.

Financial Outlook
The greatest threat to our financial operations at the present time is
the uncertainty about the level of governmental funding which pro
vided more than $21 million in fiscal 1981. The University currently
has in excess of 250 active federal grants, and nearly every one of
our laboratories will be affected by federal budget cuts.
Provision-for capital expenditures in the years ahead is an urgent
concern. A continuing need is to obtain more sophisticated equip
ment, to modernize support functions, and to comply with regulato
ry requirements that affect the operations of research laboratories.
Beginning in 1982, we will modernize older buildings as we start
several major new laboratories. The "start-up" costs of launching a
new laboratory are significant. We also will soon have to reckon with
the very large financial burden of additional housing for our faculty.
It is almost impossible to obtain governmental funds for these capi
tal expenditures, so we look primarily to private donors for our
essential needs.
The University operates on a ten-year financial plan that is updat
ed three times each year for review by the Board of Trustees. The
most recent projections show that we should again operate in the
black in fiscal 1982, but we are projecting a deficit in fiscal 1983 be
cause of the start-up costs of new laboratories. In effect, we will be
using most of the reserves built up in our operating budgets during
the last two years. Projections for the balance of the ten-year period
reflect an intent to maintain our programs at roughly the present lev
el and to conduct financial operations at break-even.

29

Reportofthe President

Government
Grants
(21.1)39%
Private
Grants
(9.7)18%

Investment
tncome
(17.2)32%

Direct
Research
and
Education
(32.1)63%

30

The Rockefeller University

The attainment of these projections will certainly require great
effort and some good luck in the face of probable levels of inflation
and likely reductions in governmental funding. But I am confident
that the quality of our work will continu� to attract the support
necessary to perform our mission.

Development Program
The detailed objectives for the current ten-year, $150-million
Development Program, which began in July 1978, are shown in
Table 3. Progress by June 30, 1981, the end of the third year of the
program, was $67.7 million, including $59 million in new gifts and
·pledges received since July 1978 and $8.7 million in payments on ear
lier pledges. This represents 45% of the ten-year goal. Not included
in the total is an additional $11.9 million in trust and estate commit
ments.
Nearly half of the ten-year total, $71 million, is being sought for
additions to endowment. I am therefore especially pleased to report
that $40.1 million of that $71 million has already been pledged. This
has provided significant added security for our financial outlook.
In my previous report, I announced the award by the Rockefeller
Brothers Fund of a five-year, unrestricted grant of $15 million with
provision for an additional $7.5-million challenge grant if two condi
tions were met by December 31, 1986: that the University raise $25
million in new endowment and that we match the $7.5 million RBF
challenge grant by additional contributions to endowment from gifts
or other sources.
I am pleased to report that by June 30, 1981, we had met and ex
ceeded the above conditions five years ahead of the deadline {in
cluding allocation of the original $15-million grant to endowment).
Subsequent discussion with officials of the Rockefeller Brothers
Fund indicates that we may anticipate early payment of the challenge
grant.
On the basis of the performance of our Development Program
since its inception in 1972, it is tempting to be optimistic about the
future. However, there are some major concerns. One of them, as I
have mentioned, is the reduction in federal funding of basic
research. Another is the impact of the 1981 Tax Reform Act, which
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Table 3. The Rockefeller University
Ten-Year Development Program, July 1978 to June 1988
ENDOWMENT

Amount

20 Endowed Professorships: ........................... $25,000,000
Fellowships:
10 University Fellowships ............... $ 8,000,000
10 Clinical Fellowships ..................· 8,000,000
20 Postdoctoral Fellowships .............. 10,000,000
50 Doctoral Fellowships ................ 20,000,000

46,000,000

Total for Endowment ............................$71,000,000
PROGRAM SUPPORT AND CAPITAL PROJECTS
Restricted Program Support
Fundamental investigations,
including molecular and cell
biology, the neurosciences,
parasitology, reproductive
biology, immunology, toxicology ........ $35,000,000
Clinical studies, including
metabolic/genetic disorders,
immunological diseases,
cancer, environmental
medicine, pharmacology ..............20,000,000
$55,000,000
Unrestricted Program Support
For use at the discretion of
the President and Trustees ............................9,000,000
Facilities
Modernization and renovation of
laboratories, hospital, and
essential support services ...........................15,000,000
Total for Program Support and Capital Projects ............$79,000,000
Grand Total ................................ $150,000,000
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is not known at this time and will not be for many months.
Nevertheless, it is the most far-reaching tax legislation in many
years, and the uncertainty about its eventual impact on philanthropy
is cause for careful attention and concern. Increased cost of housing
in New York City, the need to modernize older laboratories, con
tinuing inflation, and the signs of national economic downturn are
further causes for concern.
On the positive side, our development efforts, begun so carefully
by my predecessor Frederick Seitz a decade ago with almost no pre
vious history of institutional donors, this year reached an annual
level of $15 million in new gifts and pledges, with a momentum sug
gesting further growth. Most important, the demonstrable excel
lence of basic research and teaching at The Rockefeller University
marks it as one of the best opportunities for philanthropic "invest
ment."
The ultimate success of the Development Program rests on our
ability to identify, involve, and communicate with an expanding
constituency of individuals, corporations, and foundations. To ac
complish this, we are enlarging our programs of campus visits by in
dividuals and groups who can speak for the University and contri
bute to its financial well-being. This progress is augmented by a con
tinuing series of regional meetings and an increasing variety of
University publications. In summary, I am optimistic of achieving
our $150-million goal in good time for the 1988 target.
Finally, my sincere thanks, on behalf of the trustees and the
campus community, to all of our donors, and to the volunteers who
conduct our programs. Without this material manifestation of wide
ly based, public-spirited support from private individuals and organ
izations, we could not hope to meet our obligations to the welfare of
humankind.
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Gifts and Grants
The University's Development Program seeks $150 million by the
end of 1988.' The goals emphasize additional endowment and long
term operating support for basic research in the life sciences, clinical
programs of our hospital, endowed professorships, predoctoral and
postdoctoral fellowships, and the renovation of research facilities.
The following pages include two lists of donors for the current
two-year period. List I represents individuals, foundations, corpora
tions, and bequest gifts contributing to general goals. List II
comprises governmental and private sponsors of special projects.

Listi
Individuals
Mr. Ralph E. Ablon
Mr. and Mrs. Frederick L. Adler
Ms. Hope Aldrich
Anonymous
Mrs. Vincent Astor
Mr. Robert Bach
Mr. Albert M. Baer
AlexanderG. Beam, M.D.
Mr. George F. Bennett
Mr. Richard Bernheim
The Boorstein Family Fund
Mr. William Braden
Mr. Frank T. Cary
Mr. and Mrs. Lauristan Castleman
Mr. and Mrs. Eliot C. Clarke
Mr. and Mrs. Farnham Collins
Mr. and Mrs. Joseph C. Cornwall
Mr.Granger Costikyan
Mrs. Susan L. Cullman
Mr. Joseph H. Davenport, Jr.
Mr. and Mrs. Nicholas F. Deak
Eli Whitney Debevoise, Esq.
Mr. and Mrs. J. Richardson Dilworth
Mr. Eugene F. Di Paola
Mr. Frank D. Orang

Mr. and Mrs. Barry W. Dress
Ms. Peggy Dulany
Mr. Royal H. Durst
Anne E. Dyson, M.D.
Mr. and Mrs. Charles H. Dyson
Mr. Burtt R. Ehrlich
Mr. and Mrs. Peter Elder
Mr. Manuel Espinosa Yglesias
Ms. Sandra Ferry
Mr. and Mrs. Edward S. Finkelstein
Mr. Richard Flender
Alexander D. Forger, Esq.
Mr. and Mrs. Leonard Franklin
Mrs. Ann Haebler Frantz
Mrs. Verena Frauenfelder
Mr. Richard M. Furlaud
Dr. and Mrs. John R.Gamble
Mr. and Mrs. Edward L. Gardner
Dr. EugeneGarfield
Mr. Patrick J.Garvey
Mr. CarlGerstacker
Mr. Seth Glickenhaus
Mr. Roger J. Goebel
Mr. and Mrs. William T.Golden
Mr. Albert S. Goldman
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In memory of EthelGoldstein
Mr. Leon Gould
Dr. and Mrs. William C. Greenough
In memory of Flora E. Griffin
Mr. and Mrs. Patrick E. Haggerty
Mr. Neil Hanlon
Mrs. Pamela Harriman
Mr. Michael Harris
Ms. Maxine Harrison
Mrs. Helen H. Harrower
Mr. Martin Heilbrunn
Mrs. Marian S. Heiskell
Mr. Christian A. Herter, Jr.
Mr. Carl B. Hess
Mr. Leon Hess
Mrs. Theodore Hetzler
Mr. and Mrs. Clifton H. Hipkins
Ms. Neva Kaiser
Mr. and Mrs. Samuel T. Kantor
Mr. Bernard Laterman
Mr. and Mrs. Jonathan E. Lazrus
Dr. and Mrs. Joshua Lederberg
Mr. H. W. Lee
Mr. Frederick G. Lehmann
Dr. and Mrs. Louis Lehrman
Mr. Martin L. Leibowitz
Ms. Catherine Levin
Dr. Philip Levine
Mr. and Mrs. Budd Levinson
Mr. Gustav 0. Lienhard
Mr. Harold F. Linder
Mr. and Mrs. James A. Linen III
Mr. Edmund W. Littlefield
Mr. Henry Luce III
Mr. Ira H. Lustgarten
John E. MacKenty, Esq.
Mr. Cyril Magnin
Mrs. Lucille Markey
Mr. John McCarthy
Dr. and Mrs. Maclyn McCarty
Dr. Ray McDermott
Richard Menaker, Esq.
Mr. and Mrs. Herman I. Merinoff

Mrs. Maurice Moore
Mr. Louis Moskowitz
Mr. RodneyW. Nichols
Mr. Albert L. Nickerson
In memory of Alfred Nogi
Mr. Suliman Olayan
Mr. and Mrs. George D. O'Neill
SirY. K. Pao
Mr. and Mrs. Thomas Parsons III
Mr. Lowell R. Patton, Jr.
Mr. Bernard Petrie
Mr. and Mrs. Harvey Picker
Mr. and Mrs. Jaime Raventos Vinal
Mr. and Mrs. Robert J. Ravitz
Mr. Gustave A. Reh, Jr.
Mrs. Helene 0. Rittenberg
Mr. Edward Robinson
Mr. David Rockefeller
Mrs. Doris L. Rosenberg
Mr. Samson Rosenblatt
Mr. Eric D. Rosenfeld
Mr. Richard Rosenthal
Mr. Fayez Sarofim
Mr. Morris M. Schrier
Mr. and Mrs. Daniel Schwartz
Mr. David C. Scott
Dr. and Mrs. Frederick Seitz
Mr. and Mrs. Phillip Shatz
Mr. and Mrs. Masood R. Siddiqi
Ms. Abby Simpson
Mr. and Mrs. Herbert M. Singer
Mr. and Mrs. Malcolm Smith
William R. Soons, Esq.
Mr. Maury L. Spanier
Mr. Michael A. Steiber
Mr. and Mrs. James A. Stern
Mrs. Lenore 0. Stern
John R. Stevenson, Esq.
Mr. and Mrs. J. Paul Sticht
Ms. Jennifer Stone
Mr. RobertG. Stone, Jr.
Mrs. Clementine M. Tangeman
Mr. and Mrs. James F. Thacher
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Count and Countess
W. A. W. vanLimburg Stirum
Mr. RobertL. Van Valer
Mr. DeWitt Wallace
Mr. Lew Wasserman
Dr. W. Gordon Whaley
Mr. Edwin C. Whitehead
Mr. and Mrs. Julius Wile
James R. Withrow, Jr., Esq.
Mr.Lester Wolfe
Mrs. Thew Wright
Mr. Wilfred Wyler
Dr. and Mrs. Richard S. Young
Dr. Chen Ning Yang
In memory of Anna Zizzo
Foundations
Achievement Rewards for College
Scientists (ARCS) Foundation, Inc.
Harriett Ames Charitable Trust
Archbold Charitable Trust
The Vincent Astor Foundation
The Robert and Ellen Bach
Foundation,lnc.
Benwood Foundation
Edith C. Blum Foundation
Brayton-Wilbur Foundation
Carrier Foundation
Mary Flagler Cary Charitable Trust
Centennial Foundation
Leo W. andLilyan E. Cole Fund
The Commonwealth Fund
Constans Culver Foundation
Dresser Foundation
Camille and Henry Dreyfus
Foundation, Inc.
Dyson Foundation
Ferdinand Eberstadt Foundation
Blanche D. Enders Trust
The Charles W. Engelhard Foundation
Sherman Fairchild Foundation, Inc.
Max C. Fleischmann Foundation

Erwin 0. and Rosalind H. Freund
Foundation
Fund for Higher Education
Herman Goldman Foundation
Hagedorn Fund
Irma T. Hirschl Charitable Trust
Jephson Educational Trust
Jonsson Foundation
Kimmelman Foundation
The Kresge Foundation
Landegger Charitable Fund
FlorinaLasker Charitable Trust
Samuel & EthelLefrak Foundation
Lemberg Foundation, Inc.
TheLeonhardt Foundation
DorotheaLeonhardt Fund of
Communities Foundation of Texas
Leonhardt Fund of the New York
Community Trust
Thayer Lindsley Trust
George Link Jr. Foundation, Inc.
Richard Lounsbery Foundation
Virginia andLeonard Marx Foundation
The McKnight Foundation
Andrew W. Mellon Foundation
Edward S. Moore Foundation, Inc.
The Perkin Fund
The Pew Memorial Trust
Harold and Beatrice Renfield Foundation
Charles H. Revson Foundation
Fannie E. Rippel Foundation
Rockefeller Brothers Fund
The Rockefeller Foundation
Billy Rose Foundation
Dorothy and Benjamin Rosenbloom
Foundation
Jon and Sue Rotenstreich Foundation
TheLewis and Marcia Schott Foundation
The Seth Sprague Educational
and Charitable Foundation Inc.
Jules and Doris Stein Foundation
The Tubman Trust
Wasserman Foundation
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Arthur K. Watson Charitable Trust
Nina W. Werblow Charitable Trust
Harry Winston Research Foundation, Inc.
TheNorman and Rosita Winston
Foundation

Corporations
Air Products and Chemicals, Inc.
Allied Corporation
Allied Chemical Foundation
Allis-Chalmers Foundation, Inc.
American Broadcasting Companies, Inc.
American IndustrialHealth Council
American Telephone
&Telegraph Company
AMF Incorporated
Amoco Foundation, Inc.
Atlantic Richfield Foundation
Bomack International Marketing
The Bowery Savings Bank
Bristol-Myers Fund
Brown&Williamson Tobacco Corp.
Celanese Corporation
The Chase Manhattan Bank, N. A.
Chevron U.S.A. Inc.
China Investment and Trust Co., Ltd.
China Technical Consultant, Inc.
Chong Tao Chemical Mfg. Co.
Consolidated Edison Company
ofNewYork
Coopers& Lybrand
Corning Glass Works Foundation
Diamond Shamrock Corporation
Dow Chemical Company
E. I. du Pont deNemours
&Company, Inc.
Ehrlich-Bober&Co., Inc.
Engelhard Minerals&Chemical Corp.
The Equitable Life Assurance Society
of the United States
Exxon Corporation
Exxon Educational Foundation
Ford Motor Company

Foremost-McKesson, Inc.
General Foods Fund
General Public Utilities Corporation
Grumman Corporation
Hooker Chemical Company
Institut Merieux
I.B.M. Corporation
International Minerals
&Chemicals Corporation
Irvin Industries Inc.
Lehman Brothers Kuhn Loeb Inc.
Thomas J. Lipton, Inc.
R.H. Macy&Co.
Merck Company Foundation
Milliken Foundation
Mitsui&Co. (U.S.A.), Inc.
Mobil Foundation, Inc.
Mobil Research
& Development Corporation
Monsanto Company
Monsanto Fund
Monumental Corporation
Morgan Guaranty Trust Company
ofNewYork
Morgan Stanley&Co., Inc.
Morgan Stanley Foundation
Motorola Foundation
National Distillers and
Chemical Corporation
Nestle Company, Inc.
NewYork Telephone Company
Ogden-American Corporation
Olin Corporation Charitable Trust
Peat, Marwick, Mitchell&Co.
Pfizer, Inc.
The Pfizer Foundation
Philip Morris Inc.
PPG Industries Foundation
Purolator, Inc.
The Rapid-American Corporation
Revlon, Inc.
Revlon Foundation, Inc.
R. J. Reynolds Industries, Inc.
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Rohm & Haas Company
Seiden & deCuevas Inc.
Shell Companies Foundation
Squibb Corporation
The Squibb Institute
for Medical Research
Standard Oil Company of California
Standard Oil Co. (Ohio)
Stauffer Chemical Company
Sun Chemical Corporation
Taiwan Cement Corp.
Tandy Corporation
Tennessee Eastman Company
Transamerica Corporation
The Travelers Corporation
Union Carbide Corporation
Union Pacific Foundation
United Polymer Corp.
USI Far East Corporation
Volunteer State Life
Insurance Company
Western Electric Fund
John Wiley & Sons, Inc.
The Xerox Foundation

Bequests and Memorial Funds
Estate of Bernard Baumann
Estates of Alfred E. and Ruth Cohn
Estates of Mack J. & Henrietta B. Hirsch
Estate of Harry C. Keiner
Estate of Abby Rockefeller Mauze
Estate of Frances Sambur
In memory of Patrick E. Haggerty
In memory of Dr. William H. Stein
In memory of Jacqueline Susann

List II
Abraham Foundation, Inc.
The Adler Foundation
Agency for International Development
Akzona, Inc.
Rita Allen Foundation
American Cancer Society, Inc.
American Chemical Society,
Petroleum Research Fund
American Cyanamid Co.
American Diabetes Association
American Egg Board
American Heart Association
American Liver Foundation
American Social Health Association
Harriett Ames Charitable Trust
AMF Incorporated
The Arthritis Foundation, Inc.
Bergen/Szebro
Best Foods Company
Bio-Dynamics, Inc.
Susan E. B. Bloomberg Foundation, Inc.
Boehringer-Mannheim
Bristol-Myers Company
Burroughs Wellcome Fund
Cancer Research Institute
Mr. Bruce Carp
Centers for Disease Control
Cetus Corporation
Frank M. Chapman Memorial Fund
The Chicago Community Trust
The Jane Coffin Childs Memorial Fund
for Medical Research
The Marilyn B. and Stanley L. Cohen
Foundation, Inc.
The Continental Group Foundation, Inc.
AHEP A Cooley's Anemia Foundation
Cooley's Anemia Blood & Research
Foundation for Children, Inc.
Cooley's Anemia Volunteers, Inc.
Cooper Laboratories
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Cutter Laboratories, Inc. Bayuet Division
Cystic Fibrosis Foundation
Mr. Robert Dall
The Dover Fund, Inc.
The Camille and Henry Dreyfus
Foundation, Inc.
E. I. du Pont de Nemour�
& Company, Inc.
Electric Power Research Institute
Enzo Biochem, Inc.
Mr. and Mrs. Michael H. Epstein
European-American Bank
& Trust Company
European Association for
the Study of Diabetes
Fight for Sight
Mr. Thomas C. Fogarty
The Ford Foundation
FRS Associates
The Raymond L. Golden
Family Foundation, Inc.
Mr. Fred P. Goldhirsch
Greenwich Savings Bank
The Harry Frank Guggenheim
Foundation
The John A. Hartford Foundation, Inc.
The Heiser Program for Research
in Leprosy
Hoffmann-LaRoche Inc.
Mr. Sidney Homer
Mr. and Mrs. Donald Hupe
International Research
of Microbiology
Ives Laboratories Inc.
Robert Wood Johnson Foundation
Alfred Jurzykowski Foundation
Juvenile Diabetes Foundation
Max Kade Foundation
John L. and Helen Kellogg Foundation
The Klingenstein Fund
The Kroc Foundation
Leukemia Society of America, Inc.

Mr. Kenneth Lipper
John D. and Catherine T.
MacArthur Foundation
The McKnight Foundation
Mrs. Elizabeth L. McMaster
The Medical Foundation, Inc.
The Medical Letter
on Drugs & Therapeutics
Medical Research Council of Canada
Merck and Company
Merck, Sharpe & Dohme
Research Laboratories
Miles Laboratories
Mrs. Sonya Wohl Mirsky
Muscular Dystrophy Association
National Dairy Council
The National Foundation
National Institute of Education
National Kidney Foundation
National Leukemia Association
National Multiple Sclerosis Society
National Science Foundation
New York Community Trust
New York Heart Association
New York State Health Research Council
New York State Division
of Substance Abuse Services
Novo Laboratories, Inc.
Mr. John L. O'Grady
Organon, Inc.
The Pack Foundation
for Medical Research
Pan American Health Organization
Dr. and Mrs. Lewis C. Park
Pfizer, Inc.
The Population Council
Public Health Service,
National Institutes of Health
Mr. and Mrs. Lewis Ramieri
Rhone-Poulenc, Inc.
The Rockefeller Foundation
Damon Runyon-Walter Winchell
Cancer Fund
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Sandoz, Inc.
G. D. Searle & Company Laboratories
Shell Development Company
S.L.E.Foundation of America
Alfred P.Sloan Foundation
Mr. Layton F.Smith
Smith Kline and French Laboratories
Smith Kline Animal Health Products
Syntex USA, Inc.
Mr. Herbert Tenzer
3M Foundation
U.S.Army Medical Research
and Development Command
U.S.National Aeronautics & Space
Administration

U.S. Department of Agriculture Science
and Education Administration
U.S. Department of Energy
The Upjohn Company
The Vanneck-Bailey Foundation
The Voute Foundation, Inc.
Walter Gabriel Wasser, M.D.
The Weight Watchers Foundation
The Weizmann Institute of Science
The Whitehall Foundation, Inc.
The Helen Hay Whitney Foundation
Mr.and Mrs. William N.Wight
World Health Organization

(Lists cover period July 1, 19 79 -December 31, 1981)
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1979-1981 Roster of Members
The Rockefeller University Council
The Rockefeller University Council actively.assists the University in
heightening public awareness of the uses and consequences of the
knowledge developed through basic research, clinical investigations
and advanced education. By helping disseminate a broader apprecia
tion of the University's work, the Council plays a key role in estab
lishing a growing base of voluntary private support for the institu
tion.
Chairman
James A. Linen III
Trustee of the University

Members
Charles F. Adams
Chairman, Finance Committee
Raytheon Company
Lexington, Mass.
Susanna Agnelli
Rome, Italy
Norman E. Alexander, Chairman
Sun Chemical Corporation
New York, N.Y.
Herbert A. Allen
Allen & Company Inc.
New York, N.Y.
William S. Anderson
Chairman and Chief Executive Officer
NCR Corporation
Dayton, Ohio
Albert M. Baer, Chairman
Imperial Knife Associated Cos.
New York, N.Y.
Charles F. Barber, Chairman
ASARCO Inc.
New York, N.Y.
John R. Beckett, Chairman
Transamerica Corporation
San Francisco, Cal.

Karl R. Bendetsen, Director
Champion International Corporation
Washington, D.C.
Dr. Albert Bowers, President
Syntex Corporation
Palo Alto, Cal.
Anthony J. A. Bryan
Chairman and President
Copperweld Corporation
Pittsburgh, Pa.
Donald C. Burnham, Director, Officer
Westinghouse Electric Corporation
Pittsburgh, Pa.
Dr. Ronald E. Cape, Chairman
Cetus Corporation
Berkeley, Cal.
Edward W. Carter, Chairman
Carter Hawley Hale Stores, Inc.
Los Angeles, Cal.
Guy Charlap
Greenwich, Conn.
Gustavo A. Cisneros, President
Organizacion Diego Cisneros
Caracas, Venezuela
Granger Costikyan
Brown Brothers Harriman & Co.
New York, N.Y.
Morris D. Crawford, Jr.
Chairman of Executive Committee
The Bowery Savings Bank
New York, N.Y.
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Susan L. Cullman
Briarcliff Manor,N.Y.
Joseph H. Davenport, Jr.,Chairman
Volunteer State Life Insurance Co.
Chattanooga,'fenn.
Michel David-Weill
Lazard Freres & Company
New York,N.Y.
Dr. Edward E. David,Jr.,President
Exxon Research
& Engineering Company
Florham Park,N.J.
John Diebold,Chairman
The Diebold Group,Inc.
New York,N.Y.
John T. Dorrance,Chairman
Campbell Soup Company
Camden,N.J.
Dr. Anton Caspar R. Dreesmann,
Chairman
Vroom & Dreesmann B.V.
Amsterdam,Netherlands
Charles H. Dyson,Chairman
Dyson-Kissner-Moran Corporation
New York,N.Y.
Oscar Dystel,Consultant
Bantam Books,Inc.
New York,N.Y.
James L. Ferguson Chairman
General Foods Corporation
White Plains,N.Y.
Dr. Stanley D. Frank President
CBS Educational and
Professional Publishing
New York,N.Y.
H. Clay Frick II,M.D.
Columbia Presbyterian Hospital
New York,N.Y.
Robert W. Galvin,Chairman
Motorola,Inc.
Schaumburg,Ill.
Dr. Eugene Garfi�ld
Chairman and President
Institute for Scientific Information
Philadelphia,Pa.

Carl A. Gerstacker,Director
The Dow Chemical Company
Midland,Mich.
William C. Gibson,M.D.,Chairman
Universities Council
of British Columbia
Vancouver, Canada
William T. Golden
New York,N.Y.
Dr. William C. Greenough
Chairman,CREF Finance Committee
Teachers Insurance & Annuity Assoc.
New York,N.Y.
Sumio Hara,Executive Advisor
Bank of Tokyo, Ltd.
Tokyo, Japan
John D. Harper,Director
Aluminum Company of America
Pittsburgh, Pa.
S. T. Harris,Director
Texas Instruments Inc.
Dallas, Texas
Dr. Alexander Heard, Chancellor
Vanderbilt University
Nashville,Tenn.
Louis J. Hector,Esq.
Steel, Hector & Davis
Miami,Fla.
Marian S. Heiskell,Director
The New York Times

New York,N.Y.
Christian A. Herter,Jr.
Santa Fe,New Mexico
Carl B. Hess,President
AEA Investors Inc.
New York,N.Y.
Leon Hess
Chairman of the Board
Amerada Hess Corporation
New York,N.Y.
The Honorable
A. Leon Higginbotham,Jr.
U.S. Court of Appeals, Third Circuit
Philadelphia, Pa.
Ada Louise Huxtable
The New York Times

New York,N.Y.
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Vernon E. Jordan, Jr.
President
National Urban League, Inc.
New York, N.Y.
Dr. George F. Kirby, Chairman
Texas Eastern Corporation
Houston, Texas
Antonie T. Knoppers, M.D.
Summit, N.J.
Baron Leon Lambert
Groupe Bruxelles Lambert S.A.
Brussels, Belgium
Dr. Gerald D. Laubach, President
Pfizer Inc.
New York, N.Y.
Mary Wells Lawrence, President
Wells, Rich, Greene, Inc.
New York, N.Y.
Ralph Lazarus, Chairman
Federated Department Stores, Inc.
Cincinnati, Ohio
Gustav 0. Lienhard, Chairman
The Robert Wood Johnson Foundation
Princeton, N.J.
Edmund W. Littlefield
Chairman, Executive Committee
Utah International Inc.
San Francisco, Cal.
John H. Loudon
The Hague, Netherlands
Henry Luce III, President
The Henry Luce Foundation, Inc.
New York, N.Y.
Bayless Manning, Esq.
Paul, Weiss, Rifkind, Wharton
& Garrison
New York, N.Y.
Dean A. McGee, Chairman
Kerr-McGee Corporation
Oklahoma City, Okla.
Robert S. McNamara
Washington, D.C.
Herman I. Merinoff, President
Renfield Corporation
New York, N.Y.

Dr. Ruben F. Mettler, Chairman
TRW,Inc.
Cleveland, Ohio
Elisabeth L. Moore
New Yor)<., N.Y.
Phil R. North, Chairman
Tandy Corporation
Fort Worth, Texas
Anthony J. F. O'Reilly, President
H. J. Heinz Company
Pittsburgh, Pa.
Suliman S. Olayan, Chairman
The Olayan Group
Jeddah, Saudi Arabia
Sir Yue-Kong Pao, Chairman
World-Wide Marine, Inc.
Hong Kong
Gladys T. Perkin, Trustee
The Perkin Fund
New Canaan, Conn.
Carl H. Pforzheimer, Jr., Senior Partner
Carl H. Pforzheimer & Company
New York, N.Y.
Pierre Philippe, Managing Director
Pan-Holding S.A.
Paris, France
Gerard Piel, President
Scientific American Inc.
New York, N.Y.
Claude Ramsey
Chairman and President
Akzona Inc.
Asheville, N.C.
Dr. Gordon N. Ray, President
John Simon Guggenheim
Memorial Foundation
New York, N.Y.
Dina Merrill Robertson
New York, N.Y.
James D. Robinson III, Chairman
American Express Company
New York, N.Y.
Louis H. Roddis, Jr., P. E.
Consulting Engineer
Charleston, S.C.
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Lord Roll oflpsden, Chairman
S. G. Warburg&Company, Ltd.
London, England
Dr. George Rosenkranz, Chairman
Syntex Corporation
Mexico, D.F.
Dr. Anton E. Rupert, Chairman
Rembrandt Group of Companies
Capetown, South Africa
Arthur M. Sackler, M.D.
New York, N.Y.
Richard B. Salomon
Riverbank Associates
New York, N.Y.
Fayez Sarofim, President
Fayez Sarofim&Company
Houston, Texas
Noma Sarofim, Vice President
Morgan Stanley &Co.
New York, N.Y.
Morris M. Schrier, Legal Consultant
MCA Inc.
New York, N.Y.
Natalie Schwartz
Rancho Mirage, Cal.
Richard J. Schwartz, President
Jonathan Logan, Inc.
New York, N.Y.
David C. Scott, Chairman
Allis-Chalmers Corporation
Milwaukee, Wis.
Dr. Frederick Seitz, President Emeritus
The Rockefeller University
New York, N.Y.
M. B. Seretean, Chairman
Coronet Industries, Inc.
Dalton, Ga.
Dr. Olavo E. Setubal, President
Bancoltau
Sao Paulo, Brazil
Richard R. Shinn, Chairman
Metropolitan Life Insurance Co.
New York, N.Y.
Sargent Shriver, Esq.
Fried, Frank, Harris,
Shriver& Kampelman
Washington, D.C.

Herbert M. Singer, Esq.
Singer&Corwin
New York, N.Y.
Dr. Dieter Spethmann, Chairman
Thyssen A.G.
Dusseldorf, West Germany
Dr. Chauncey Starr, Vice Chairman
Electric Power Research Institute
Palo Alto, Cal.
John R. Stevenson, Esq.
Sullivan&Cromwell
New York, N.Y.
Colin Stokes, Director
R. J. Reynolds Industries, Inc.
Winston-Salem, N.C.
Robert G. Stone, Jr., Chairman
West India Shipping Company, Inc.
New York, N.Y.
Clementine M. Tangeman
New York, N.Y.
Howard S. Turner
Chairman of the Executive Committee
Turner Construction Company
New York, N.Y.
Grace S. Vance
New York, N.Y.
Dr. Paulo Villares
Chairman of the Board and President
Industrias Villares S.A.
Sao Paulo, Brazil
Edwin C. Whitehead, Chairman
Technicon Corporation
Tarrytown, N.Y.
Charles Wohlstetter, Chairman
Continental Telephone Corporation
New York, N.Y.
Lester Wolfe
New York, N.Y.
William T. Ylvisaker, Chairman
Gould Incorporated
Rolling Meadows, Ill.
Margaret B. Young, Chairman
Whitney M. Young, Jr.
Memorial Foundation
New York, N.Y.
(Current as ofJuly 1, 1981)
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The Rockefeller University Board of Trustees
1979-1981
RalphE. Ablon, Vice
Chairman of the Board
Brooke (Mrs. Vincent) Astor
William 0. Baker, Chairman of the Board
AlexanderG. Beam
George F. Bennett
Curtis L. Blake 1
Nicholas F. Brady
Ronald C. Breslow 3
Paul A. Cameron 2
Frank T. Cary
ThomasG. Cousins
J. Richardson Dilworth
ThomasE. Drohan 2
Alexander D. Forger
Richard M. Furlaud
PatrickE. Haggerty 5
David A. Hamburg
Philip Handler 6
Pamela C. (Mrs. W. Averell) Harriman
Louis J. Hector 3
Marian S. (Mrs. Andrew) Heiskell 4

Neva Kaiser
Seymour S. Kety
Joshua Lederberg, President
James A. Linen III
Albert L. Nickerson
Frank Press 3
Norman F. Ramsey
AnneE. Reed
David Rockefeller, Chairman
of theExecutive Committee
Walter N. Rothschild, Jr.4
J. Paul Sticht
RobertG. Stone, Jr. 4
Lewis Thomas
P. Roy Vagelos
I. Elected February, 1980
2. Elected October, 1980
3. Elected October, 1981
4. Term Expired October, 1980
5. Died, October I, 1980
6. Died, December 29, 1981

